Construction and Effectiveness of the
Pharmaceutical Control System of Injection Proton Pump Inhibitors

Abstract

Abstract: Objective： To establish a pharmaceutical control system of injection proton pump inhibitors（I-PPIs）， and compare the application of I-PPIs before and after control. Methods： The hospital information system was used to collect I-PPIs related usage data from 2018 to 2021 in the People's Hospital of Lijiang City Affiliated to Kunming University of Science and Technology. Statistical analysis was conducted on the inpatient usage rate， medication frequency， usage intensity， and medication cost ratio of I-PPIs. Results： Compared with before control， medication frequency， usage intensity， intensity of medication， and medication cost ratio of I-PPIs after control were significantly decreased， rational utilization rate was increased. The number of inappropriate medication cases including no indication of preventive medication and longer course of treatment were significantly decreased. Conclusion： The establishment of pharmaceutical control system of I-PPIs can effectively promote the clinical application and control of medicine， and effectively guarantee the medicine safety of patients.

Key words: font-family:Times New Roman, ">proton pump inhibitorsfont-family:Times New Roman, ">；font-family:Times New Roman, "> pharmaceutical control systemfont-family:Times New Roman, ">；font-family:Times New Roman, "> clinical application

CLC Number:

Li Xiaoji, Li Guorong.

Construction and Effectiveness of the Pharmaceutical Control System of Injection Proton Pump Inhibitors [J]. Journal of Dali University, 2023, 8(8): 44-48.

References

〔1〕龚巧燕，朱洪，陈俞先，等.四川省88家三级医院重点监控药品管理现状调查分析〔J〕.中国现代应用药学，2021， 38（17）：2134-2139.

〔2〕 REEVE E， ANDREWS J M， WIESE M D， et al. Feasibility of a Patient Centered Deprescribing Process to Reduce Inappropriate Use of Proton Pump Inhibitors〔J〕.Ann Pharmacother，2015，49（1）：29-38.

〔3〕 UEBERSCHAER H， ALLESCHER H D. Proton Pump Inhibitor-Side Effects and Complications of Long-Term Proton Pump Inhibitor Administration〔J〕. Z Gastroenterol，2017，55（1）：63-74.

〔4〕李莉，邵兵，刘琳琳，等.质子泵抑制剂在预防外科手术患者围手术期应激性溃疡的应用分析〔J〕. 实用药物与临床，2021，24（2）：142-145.

〔5〕 CRAIG D G N， THIMAPPA R， ANAND V， et al. Inappropriate Utilization of Intravenous Proton Pump Inhibitors in Hospital Practice： A Prospective Study of the Extent of the Problem and Predictive Factors〔J〕. QJM， 2010，103（5）：327-335.

〔6〕 PRATT N L， KALISCH ELLETT L M， SLUGGETT J K， et al. Use of Proton Pump Inhibitors among Older Australians： National Quality Improvement Programmes Have Led to Sustained Practice Change〔J〕. Int J Qual Health Care，2017，29（1）： 75-82.

〔7〕浙江省药学会.浙江省质子泵抑制剂院内合理应用管控专家共识〔J〕.中国现代应用药学，2021，38（22）：2769-2774.

〔8〕 WHOCC. ATC/DDD Index 2021〔EB/OL〕.［2021-02-22］. http：//www.whocc.no/atc_ddd_index/.

〔9〕 HEIDELBAUGH J J， KIM A H，CHANG R，et al.

Overutilization of Proton-Pump Inhibitors： What the Clinician Needs to Know〔J〕. Therap Adv Gastroenterol， 2012， 5（4）： 219-232.

〔10〕 PATTERSON BURDSALL D， FLORES H C， KRUEGER J， et al. Use of Proton Pump Inhibitors with Lack of Diagnostic Indications in 22 Midwestern US Skilled Nursing Facilities〔J〕. J Am Med Dir Assoc，2013，14（6）： 429-432.

〔11〕 VENKATARAMAN R， RASHID M， SHRESTHA H. Inappropriate Medication Use and Cost Comparison Analysis of Proton Pump Inhibitors： Evidence from an Indian Tertiary Care Facility〔J〕. Curr Drug Saf， 2020， 15（2）： 147-155.

〔12〕边萌，陈淑敏，史卫忠，等. 2014—2020年我国六城市重症医学科质子泵抑制剂用药现状调查与分析〔J〕. 临床药物治疗杂志， 2022， 20（2）： 32-38.

〔13〕袁洪.湖南省质子泵抑制剂的临床应用指导原则（试行）〔J〕.中南药学，2016，14（7）：673-683.

〔14〕质子泵抑制剂预防性应用专家共识写作组.质子泵抑制剂预防性应用专家共识（2018）〔J〕.中国医师杂志， 2018，20（12）：1775-1781.

〔15〕抗栓治疗消化道损伤防治专家组. 抗栓治疗消化道损伤防治中国专家建议（2016·北京）〔J〕. 中华内科杂志， 2016， 55（7）： 564-566.

〔16〕中国抗癌协会肿瘤临床化疗专业委员会，中国抗癌协会肿瘤支持治疗专业委员会. 肿瘤药物治疗相关恶心呕吐防治中国专家共识（2019版）〔J〕. 中国医学前沿杂志（电子版）， 2019， 11（11）： 16-26.

〔17〕 LUO H， FAN Q， XIAO S， et al. Changes in Proton Pump Inhibitor Prescribing Trend over the Past Decade and Pharmacists' Effect on Prescribing Practice at a Tertiary Hospital〔J〕. BMC Health Serv Res， 2018， 18（1）： 537.

〔18〕 YING J， LI L C， WU C Y， et al. The Status of Proton Pump Inhibitor Use： A Prescription Survey of 45 Hospitals in China〔J〕. Rev Esp Enferm Dig， 2019， 111（10）： 738-743.

〔19〕 AHN J S， EOM C S， JEON C Y， et al. Acid Suppressive Drugs and Gastric Cancer： A Meta-Analysis of Observa-tional Studies〔J〕. World J Gastroenterol， 2013， 19（16）：2560-2568.

〔20〕 TANG Y， ZHANG X， YANG C， et al. Application of Propensity Scores to Estimate the Association between Government Subsidy and Injection Use in Primary Health Care Institutions in China〔J〕. BMC Health Serv Res， 2013，13：183.

〔21〕沈爱宗，张圣雨，陈泳伍，等.我院多部门协作处方点评模式在重点监控药品管理中的实践〔J〕.中国药房， 2020，31（13）：1646-1649.

〔22〕汪华君，赵蓉，谭才宏. PDCA循环管理对降低质子泵抑制剂临床不合理用药的效果分析及其对策〔J〕. 抗感染药学，2019，16（9）：1500-1503.

[1]	Li Jing, Ling Haowei, Shi Kaixuan, Liu Rong, Xiao Chaojiang, Jiang Bei, . Study on Chemical Constituents of the Root of Agapetes lacei var. tomentella [J]. Journal of Dali University, 2023, 8(8): 1-5.
[2]	Ling Haowei, Li Jing, Shi Kaixuan, Liu Rong, Xiao Chaojiang, Jiang Bei, . Study on Chemical Constituents of Gentiana nanobella [J]. Journal of Dali University, 2023, 8(8): 6-10.
[3]	Shi Kaixuan, Li Jing, Ling Haowei, Liu Rong, Xiao Chaojiang, Jiang Bei, . Study on Chemical Constituents of Leptodermis pilosa [J]. Journal of Dali University, 2023, 8(8): 11-14.
[4]	Qin Zikang, Guo Haihui, Shan Fang, Wu Lei, Wang Fusheng. Synthesis of L-5-Hydroxytryptophan Derivatives [J]. Journal of Dali University, 2023, 8(8): 15-20.
[5]	Shan Fang, Guo Haihui, Qin Zikang, Li Chunxu, Wang Fusheng. Synthesis of Gentiournoside D Amide Derivatives [J]. Journal of Dali University, 2023, 8(8): 21-24.
[6]	Lai Yuxia, Guo Haihui, Qin Zikang, Shan Fang, Wang Fusheng. Optimization of Ｓelective Ester Hydrolysis Conditions for Depresteroside [J]. Journal of Dali University, 2023, 8(8): 25-29.
[7]	Lu Xixing, Zhu Ling, Wu Hao, Zhang Chenggui, Yang Yongshou, Chen Zhipeng, Liu Heng, . Chemical Composition Analysis and Multicomponent Content Determination of Extracts of Periplaneta americana from Different Breeding Plants [J]. Journal of Dali University, 2023, 8(8): 30-38.
[8]	Su Baoshun, Liu Zhitong. Preliminary Study on Antibacterial Effect and Active Parts of Dobinea delavayi [J]. Journal of Dali University, 2023, 8(8): 39-43.
[9]	Ye Shengying, Wang Xinrui, Gao Jingwen, Qin Yan. The Protective Effect of Ghrelin on High Glucose-Induced Ｈepatocellular Injury [J]. Journal of Dali University, 2023, 8(8): 49-53.
[10]	Deng Wenbin, Huang Shiqiong, Wang Xue, Li Lihua. Effects of High Salt Intervention on Proliferation and Migration of Human Aortic Vascular Smooth Muscle Cell [J]. Journal of Dali University, 2023, 8(8): 54-58.
[11]	Zhi Hongfang, Chen Xin, Zhang Jianyan, Wang Chengcheng, Zhang Yun, Yang Xuantao. Expression of RIP140 and LCOR in High-Grade Cervical Intraepithelial Neoplasia [J]. Journal of Dali University, 2023, 8(8): 59-63.
[12]	Wu Maofang, Shi Wen, Xiao Shouyong, Cai Jingjing, Liu Zengping, Fang Hong. Propensity Score Matching Analysis of Postoperative Radiotherapy in Patients with Stage ⅢA/N2 Non-Small Cell Lung Carcinoma [J]. Journal of Dali University, 2023, 8(8): 64-70.
[13]	Xiao Min, Xiong Miaomiao, Cheng Mingjing, Cui Xiuyu, Zhao Yuanqi, Zhao Weidong. Scientometric Analysis of Ferroptosis Literature Based on Web of Science #br# [J]. Journal of Dali University, 2023, 8(8): 71-77.
[14]	Rao Yanhua, Wu Xingjun, Quan Yuan, Guan Qingni, Wang Suorong, Tian Ying. Study on the Elderly Care Career-Selection Motivation and Influencing Factors of Vocational Nursing Students [J]. Journal of Dali University, 2023, 8(8): 78-83.
[15]	Ma Yongxin, Ao Bo, Yang Guoqin, He Lixiu, Qian Jinfu. Qualitative Study on Professional Identity and Motivation for Enrollment of Midwifery Undergraduates in Yunnan Province [J]. Journal of Dali University, 2023, 8(8): 84-87.

Construction and Effectiveness of the Pharmaceutical Control System of Injection Proton Pump Inhibitors

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments